Cancer Network Staff

Saum Ghodoussipour, MD, provided an in-depth analysis of the RAMPART readout, exploring the DFS benefit of a durvalumab/tremelimumab combination in RCC.

A nurse-integrated mobile exercise app showed high usability, 80% exercise adherence, and significant fatigue improvements in a pilot study of adolescents with cancer.

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.

Switching to camizestrant plus CDK4/6i upon ESR1 mutation detection demonstrated a PFS of 7.6 months and achieved significant PFS2 benefit in SERENA-6.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Atebimetinib plus modified gemcitabine/nab-paclitaxel demonstrated an ORR of 36% and median OS of 17.3 months in first-line metastatic pancreatic cancer.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.

Cost-utility analysis of the CHALLENGE trial showed structured exercise following adjuvant chemotherapy for colon cancer is cost-saving and improves QALYs.

Neoadjuvant ipilimumab plus nivolumab and relatlimab achieved a major pathologic response in 73.7% of patients with resectable stage III/IV melanoma.

The phase 3 HARMONi-6 trial showed ivonescimab plus chemotherapy significantly improved OS vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

FOLFIRI is viable as a chemotherapy backbone with the BREAKWATER regimen as a treatment for patients with frontline BRAF V600E-mutant metastatic colorectal cancer.

Data from the phase 3 CIRCULATE trial may justify ctDNA-guided treatment escalation strategies in pMMR stage II colon cancer.

A remote mobile health intervention tripled the odds of CRC screening completion in at-risk childhood cancer survivors in the randomized ASPIRES trial.

Patients in this multiple myeloma population who received DVRd achieved an overall MRD-negativity rate at 10–5 sensitivity of 61.1% vs 40.0% with VRd.

Serial ctDNA assessment after 3 months of adjuvant chemotherapy stratified recurrence risk and identified which patients with resected CRC benefit from extended treatment.

A personalized neoantigen vaccine plus an anti-PD-1 was feasible, safe, and generated durable anti-tumor immune responses in newly diagnosed glioblastoma.

In the phase 3 PEAK trial, bezuclastinib plus sunitinib produced a median PFS of 16.5 months vs 9.2 months for sunitinib monotherapy in advanced GIST.

The assay may identify a group comprising approximately two-thirds of patients who do not have a meaningful chance of benefit from adjuvant chemotherapy.

Teclistamab monotherapy significantly improved PFS and OS vs investigator's choice in the phase 3 MajesTEC-9 trial in RRMM.

Yelena Y. Janjigian, MD, presented safety findings from DESTINY-Gastric03 at the 2026 ASCO Annual Meeting in HER2-expressing advanced gastric, GEJ, or esophageal adenocarcinoma.

A deep learning analysis of tumor microenvironment features using QuantCRC and ctDNA improved prognostic discrimination in stage III colon cancer.

The 48-month OS rate was 78.6% with pembrolizumab vs 60.4% with placebo among patients with advanced or recurrent endometrial cancer.

Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer.

Long-term follow-up from the phase 3 RUBY trial revealed a 54% estimated cure rate with the dostarlimab combination in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Saum Ghodoussipour, MD, suggested that advances in liquid biopsy tracking, next-generation ADCs, and organ-sparing approaches may be featured at ASCO 2026.

The regulatory submission was supported by results from the phase 3 PEAK trial which evaluated the combination against standard second-line monotherapy.

Nathan Goodyear, MD, explained why exercise must be treated as a precise, prescribable therapy in oncology to combat AEs and improve long-term survival.